Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | OTHER |
| Bravis Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
A randomised controlled triall (RCT) with three parallel arms comparing the functional outcome of chemical ablation with phenol and radiofrequency ablation (RFA) of the genicular nerves with conservative treatment in patients with chronic knee pain caused by osteoarthritis (OA).
In guidelines for knee osteoarthritis (OA), conservative treatments are physical therapy, analgesics and intra-articular injections with corticosteroids. In severe OA and persisting symptomatic cases the golden standard is joint replacing surgery. A less invasive technique is ablation of the sensory (genicular) nerves of the knee. This technique is beneficial for younger patients as a bridge to surgery or patients that cannot undergo total knee arthroplasty (TKA) due to comorbid health conditions. Nerve ablation can either be done with chemical agents or thermal energy.
Although there are numerous studies on genicular nerve block for chronic knee pain caused by OA, there are just a few small studies that compare genicular nerve block with conservative treatment.To be able to determine if genicular nerve ablation is efficacious to serve the gap between conservative treatment and TKA, this randomised controlled trial (RCT) compares two forms of genicular nerve ablation (radiofrequency and phenolisation; intervention) with conservative treatment (control) up to 6 months after treatment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chemical ablation of the genicular nerves with Phenol 6% | Active Comparator | Chemical ablation with phenol is done by injection of 1,5ml of phenol 6 % at the superomedial, the superolateral and the inferomedial genicular nerve. |
|
| Radiofrequency ablation (RFA) of the genicular nerves | Active Comparator | In our study we will make two RFA lesions at every target with 80°C for 90 seconds with a 5mm active tip. So we will make 6 lesions in total. The targets are the superomedial, the superolateral and the inferomedial genicular nerve. |
|
| Conservative treatment | No Intervention | Examples of allowed conservative treatments during the study are patient education, physical therapy, weight loss and different pharmacological treatments. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Diagnostic genicular nerve block | Procedure | Diagnostic block will be done with 1,5ml of Lidocaine 2% at the 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve. |
| Measure | Description | Time Frame |
|---|---|---|
| Knee function measured with the Oxford Knee score (OKS) | Questionnaire with 12 items. Scores can range from 0 to 48, with 48 being the best outcome and a lower score indicates more functional limitations and pain. | During intake, before the intervention or study start in conservative group (T=0) and during the follow up visits (T=1 at 6weeks, T=2 at 3 months, T=3 at 6 months and T=4 at 12 months after the intervention or study start). |
| Measure | Description | Time Frame |
|---|---|---|
| Osteoartritis (OA) measured by the Western Ontario and McMaster Universities Arthritis Index (WOMAC) | We will use the WOMAC in the Likert version where question are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. So the sum of the scores ranges from 0 (the best) to 96 (the worse). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gezina Oei, MD,PhD | Contact | 0031229257257 | g.t.m.l.oei@dijklander.nl | |
| Aine Honohan, MSc | Contact | 0031646340596 | a.g.honohan@Dijklander.nl |
| Name | Affiliation | Role |
|---|---|---|
| Gezina Oei, MD, PhD | Academic Medical Centre Amsterdam | Principal Investigator |
| Markus Hollmann, Prof | Academic Medical Centre Amsterdam | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dijklander Ziekenhuis | Recruiting | Hoorn | North Holland | 1624NP | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40623740 | Derived | Wit PR, Beek RV, Schokker M, Wensing C, Hollmann MW, Kallewaard JW, Oei G; RADIOPHENOL collaborators; Collaborative group name. Genicular nerve radiofrequency ablation, phenol neurolysis or conservative medical management in patients with knee osteoarthritis: protocol for the RADIOPHENOL randomised controlled multicentre trial with three parallel groups. BMJ Open. 2025 Jul 6;15(7):e094576. doi: 10.1136/bmjopen-2024-094576. |
Not provided
Not provided
The study protocol and the final data will be published. Conditions for reuse apply: A de-identified dataset will be made available upon request to the corresponding author. The request must include ethics approval and a statistical analysis plan.
An embargo period applies: The embargo period is at least 1 year after the publication of the original study.
Not provided
An embargo period applies: The embargo period is at least 1 year after the publication of the original study.
A de-identified dataset will be made available upon request to the corresponding author. The request must include ethics approval and a statistical analysis plan. Digital data and documentation will be preserved for 15 years.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Genicular nerve block with Radiofrequency Ablation (RFA) | Procedure | Genicular nerve block with RFA will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve. Radiofrequency ablation (RFA) is performed by creating two RFA lesions at the 3 treatment sites (6 lesions in total) after local anesthesia with 1,5ml lidocaine 2%. The lesions are made by heating the 5mm active tip of the needle to 80°C for 90 seconds. |
|
| Genicular nerve block with Phenol 6% | Procedure | Genicular nerve block with Phenol 6% will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve. Chemical ablation with phenol is done by injection of 1 ,5ml of phenol 6 % at the 3 target sites after infiltration with contrast dye to rule out intravascular injection. Because infiltration with phenol is painless, prior infiltration of the target site with al local anaesthetic is not necessary. |
|
| Before the intervention or study start in conservative group (T=0) and during the follow up visits (T=1 at 6weeks, T=2 at 3 months, T=3 at 6 months and T=4 at 12 months after the intervention or study start). |
| Pain measured with the Numeric Rating Score (NRS) | NRS will be measured in rest and during the performance based tests. | In rest during intake and in rest and during performance based tests before and after the diagnostic nerve block (if applicable), before the intervention (if applicable), 6 weeks, 3 months, 6 months and 1 year after the intervention |
| 30 seconds chair-stand test | During this test the total number of complete chair stands (up and down represents one stand) is counted. If at least a full stand is completed at 30 seconds this is counted in the total. If a person cannot stand even once then the score for the test is zero. | Before and after the diagnostic block, before the intervention (T=0), and at 6 weeks, 3 months, 6 months and 12 months follow up. In the conservative treatment group this will only be done at the applicable follow up dates. |
| 40 meters (4x10m) fast-paced walk test | The total time taken to walk the 4 × 10 m, excluding turns, of one trial is recorded and expressed as speed m/s by dividing distance (40 m) by time (seconds). Timing is paused during turns. | Before and after the diagnostic block, before the intervention (T=0), and at 6 weeks, 3 months, 6 months and 12 months follow up. In the conservative treatment group this will only be done at the applicable follow up dates. |
| 9-steps stair-climb test | Total time to ascend and descend steps for one trial is recorded in seconds. | Before and after the diagnostic block, before the intervention (T=0), and at 6 weeks, 3 months, 6 months and 12 months follow up. In the conservative treatment group this will only be done at the applicable follow up dates. |
| Health related quality of life with the EQ-5D-5L | The EQ-5D descriptive system comprises the following five dimensions, each describing a different aspect of health: MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The respondent is asked to indicate his / her health state by checking the box against the most appropriate statement in each of the five dimensions. EQ-5D comprises a short questionnaire that is cognitively undemanding, taking only a few minutes to complete. | Before the intervention or study start in conservative group (T=0) and during the follow up visits (T=1 at 6weeks, T=2 at 3 months, T=3 at 6 months and T=4 at 12 months after the intervention or study start). |
| Hospital Anxiety and Depression Scale (HADS) | The Dutch version of the HADS is a fourteen-item scale with seven items for anxiety (HADS-A) and seven items for depression (HADS-D) (49). Scoring for each item ranges from zero to three. A higher score indicates more anxiety or depression. | At T=0 (before intervention) and during T=3 (6 months after intervention) |
| Pain Catastrophizing Score (PCS) | The Pain Catastrophizing Scale (PCS) is a 13-item self-report questionnaire considered to be the most frequent and extensively studied tool to assess pain catastrophizing for chronic pain. Patients are asked to rate the degree to which they have any of the thoughts described in the questionnaire using a 5-point Likert scale ranging from 0 (never) to 4 (always). The total score is the sum of the scores for the individual items, and ranges from 0 to 52. Higher scores indicate a higher level of catastrophizing. | At T=0 (before intervention) and during T=3 (6 months after intervention) |
| Diagnostic block most appropriate cut-off value | The continuous results of the diagnostic nerve block in our study (percentage of pain relief) will be used to determine the best cut-off value for the positive outcome of the ablation. The cut-off value will be analysed with a receiver operating curve (ROC) analysis. Results equal or above this cut-off value are considered to predict a positive outcome of the ablation of the nerves, results below the cut-off value are considered to predict a negative outcome of the ablation of the nerve. For this analysis, a positive outcome of the ablation is defined as a MCID in OKS of 4.9 points at 3 months follow up. | Before and after the diagnostic block and during T=2 (3 months after intervention). |
| Patient satisfaction | The patient satisfaction with the result of treatment will be measured with a 5-point Likert scale (1-5). The patients will be asked to grade the statement 'I am satisfied with the result of the treatment' with the following options:
| During the follow up visits (T=1 at 6weeks, T=2 at 3 months, T=3 at 6 months and T=4 at 12 months after the intervention or study start). |
| Patient Global Impression of Change (PGIC) | The PGIC in pain and function will be measured with a 5-point Likert scale (1-5) on the applicable follow up visits. The patients will be asked to rate the following statements:
The options on the Likert scale are:
| During the follow up visits (T=1 at 6weeks, T=2 at 3 months, T=3 at 6 months and T=4 at 12 months after the intervention or study start). |
| Minimal Clinically Important Difference (MCID) of the OKS | We will use distribution and anchor based methods to determine the MCID on the patient reported outcomes of the OKS. | MCIDs will be determined for our population on T=1 (6weeks), T=2 (3 months) and T=3 (6 months) follow up. . |
| Minimal Clinically Important Difference (MCID) of the WOMAC | We will use distribution and anchor based methods to determine the MCID on the patient reported outcomes of the WOMAC. | MCIDs will be determined for our population on T=1 (6weeks), T=2 (3 months) and T=3 (6 months) follow up. |
| Minimal Clinically Important Difference (MCID) for the EQ-5D-5L | To determine the MCID on the patient reported outcomes of the EQ-5D-5L we will use an instrument defined method. | MCIDs will be determined for our population on T=1 (6weeks), T=2 (3 months) and T=3 (6 months) follow up. |
| Minimal Clinically Important Difference (MCID) of the 30 seconds chair-stand test | We will use distribution and anchor based methods to determine the MCID of the 30 seconds chair-stand test. | MCIDs will be determined for our population on T=1 (6weeks), T=2 (3 months) and T=3 (6 months) follow up. |
| Minimal Clinically Important Difference (MCID) of the 40 meters (4x10m) fast-paced walk test | We will use distribution and anchor based methods to determine the MCID of the 40 meters (4x10m) fast-paced walk test. | MCIDs will be determined for our population on T=1 (6weeks), T=2 (3 months) and T=3 (6 months) follow up. |
| Minimal Clinically Important Difference (MCID) of the 9-steps stair-climb test. | We will use distribution and anchor based methods to determine the MCID of the 9-steps stair-climb test. | MCIDs will be determined for our population on T=1 (6weeks), T=2 (3 months) and T=3 (6 months) follow up. |
| Adverse events | The reported treatment related or probably treatment related adverse events will be listed as numbers with frequencies per treatment. | After the diagnostic block, after the intervention (T=0), and at 6 weeks, 3 months, 6 months and 12 months follow up. |
| Medication changes | The patients will be asked to report changes in the use of NSAIDs and opioids during the follow up visits. The results will be summarised as increased use, no change, decrease in use and use of opioids will be reported as MME. | Before the intervention (T=0), and at 6 weeks, 3 months, 6 months and 12 months follow up. |
| Number of Total Knee Artroplasty's (TKA's) | The number of TKAs during the study follow up will be documented including the point in time since the intervention. If applicable, we will use the Kaplan-Meier estimator to estimate the survival function. | At 6 weeks, 3 months, 6 months and 12 months follow up. |
| Procedure time | The total procedure time of chemical ablation and RFA will be measured in minutes. The measurement starts as soon as the treating physician puts on his sterile gloves and will end when the sterile draping is taken off. | During the intervention visit (T=0) |
| Bravis Ziekenhuis | Not yet recruiting | Roosendaal | 4708AE | Netherlands |
|
| ID | Term |
|---|---|
| D010146 | Pain |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000078703 | Radiofrequency Ablation |
| ID | Term |
|---|---|
| D000078702 | Radiofrequency Therapy |
| D013812 | Therapeutics |
| D055011 | Ablation Techniques |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided